Track regulatory status, clinical trials, and published research across three jurisdictions.
Compound status overview
185+ compounds tracked across 3 jurisdictions
Research Landscape
Featured Compound
GLP-1 Receptor Agonist
Semaglutide is a once-weekly injection (sold as Ozempic for diabetes and Wegovy for weight management) or daily tablet (Rybelsus for diabetes) that mimics GLP-1, a natural gut hormone that controls blood sugar and appetite. It has become one of the most widely discussed medications in the world, with clinical trial data spanning over 50,000…
Regulatory Timeline
FDA ORIG 1
FDA SUPPL 1
FDA ORIG 1
FDA SUPPL 4
FDA SUPPL 3
FDA SUPPL 1
FDA SUPPL 8
FDA SUPPL 6
Latest Articles
Sequence similarity between a research peptide and endogenous ligands can produce unintended receptor interactions that complicate data interpretation and preclinical translation. This guide covers homology screening workflows, binding assay interpretation, computational prediction tools, and regulatory expectations for characterizing off-target binding risk. Understanding cross-reactivity is a characterization step, not a disqualifying judgment.
Short circulating half-lives remain one of the central obstacles in peptide drug development, with renal filtration and proteolytic degradation clearing most unmodified peptides within minutes to hours. N-terminal chemical modifications—including albumin-binding peptide domains, Fc fusion constructs, and emerging transthyretin-binding motifs—offer mechanistically distinct routes to extending plasma residence time. This article examines the structural design principles, comparative preclinical ph
Glucagon-like peptide-1 (GLP-1) based compounds span a structural continuum from near-native peptide sequences to heavily engineered variants incorporating non-natural amino acids, fatty acid conjugates, and albumin-binding domains. These modifications produce measurable differences in receptor binding kinetics, metabolic stability, and potency profiles in preclinical models. Understanding the mechanistic basis for this structural diversity clarifies why chemically distinct compounds targeting t
Clinical Trial Spotlight
Tirzepatide
Eli Lilly has announced positive topline results from its Phase III SUMMIT trial evaluating tirzepatide in patients with heart failure with preserved ejection fraction and obesity. The trial met its primary endpoint demonstrating statistically significant improvement in heart failure symptoms.
Trials by phase
Platform at a Glance
185
Compounds
13,277
Clinical Trials
1,288
Recruiting
447,038
Publications
Latest updates
New research publications for Oxytocin
New research publications for Colistin
News & updates
5 new publications found on PubMed for Oxytocin. Total publications: 28829 (animal: 11544, human: 13927, in vitro: 2044, reviews: 3907).
Read more →5 new publications found on PubMed for Colistin. Total publications: 12107 (animal: 1376, human: 6272, in vitro: 1781, reviews: 961).
Read more →20 new publications found on PubMed for Glucagon. Total publications: 53567 (animal: 18165, human: 28002, in vitro: 4266, reviews: 9538).
Read more →7 new publications found on PubMed for Semaglutide. Total publications: 4412 (animal: 206, human: 2543, in vitro: 98, reviews: 1247).
Read more →7 new publications found on PubMed for NAD+ (Peptide-Adjacent). Total publications: 45893 (animal: 14654, human: 14513, in vitro: 5335, reviews: 4178).
Read more →15 new publications found on PubMed for VIP. Total publications: 24205 (animal: 7787, human: 11877, in vitro: 1762, reviews: 7280).
Read more →9 new publications found on PubMed for P21. Total publications: 40503 (animal: 8495, human: 24856, in vitro: 9908, reviews: 1573).
Read more →Results posted for trial NCT05041426: Letermovir for CMV Prevention After Lung Transplantation.
Read more →